যুক্তরাজ্য - ইংরেজি - VMD (Veterinary Medicines Directorate)

boehringer ingelheim animal health uk ltd - bovine parainfluenza virus 3, bovine respiratory syncytial virus, bovine viral diarrhoea virus, mannheimia haemolytica - suspension for injection - inactivated viral and bacterial vaccine - cattle

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamithromycin - antibacterials for systemic use - cattle; pigs; sheep - cattletreatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni. the presence of the disease in the herd should be established before metaphylactic use.pigstreatment of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis and bordetella bronchiseptica.sheeptreatment of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus and fusobacterium necrophorum requiring systemic treatment.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 180.6 mg (equivalent: nintedanib, qty 150 mg) - capsule, soft - excipient ingredients: iron oxide red; titanium dioxide; hard fat; lecithin; gelatin; glycerol; iron oxide yellow; medium chain triglycerides; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 120.4 mg (equivalent: nintedanib, qty 100 mg) - capsule, soft - excipient ingredients: hard fat; lecithin; glycerol; iron oxide red; gelatin; medium chain triglycerides; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 25 mg - tablet, multilayer - excipient ingredients: maize starch; sorbitol; sodium hydroxide; iron oxide yellow; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; meglumine - micardis plus is indicated for the treatment of hypertension. treatment should not be intitiated with these combinations.

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - inactivated bovine respiratory syncytial virus, strain bio-24; inactivated bovine parainfluenza 3 virus, strain bio-23; inactivated mannheimia (pasteurella) haemolyica, a1 strain dsm 5283 - suspension for injection - . - inactivated viral and inactivated bacterial vaccines

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - inactivated bovine respiratory syncytial virus, strain bio-24; inactivated bovine parainfluenza 3 virus, strain bio-23; inactivated mannheimia haemolytica serotype a1 strain dsm 5283; inactivated bovine viral diarrhoea virus, strain bio-25 - suspension for injection - . - inactivated viral and inactivated bacterial vaccines

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sodium hydroxide; sorbitol; microcrystalline cellulose; iron oxide red; maize starch; lactose monohydrate; povidone; sodium starch glycollate - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: povidone; sodium hydroxide; microcrystalline cellulose; lactose monohydrate; sorbitol; sodium starch glycollate; maize starch; meglumine; magnesium stearate; iron oxide red - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium hydroxide; sorbitol; meglumine - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)